SSA
ACRV icon

Schonfeld Strategic Advisors’s Acrivon Therapeutics ACRV Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,428
Closed -$39.6K – 2159
2025
Q4 		$39.6K Buy
+16,428
New +$35.7K ﹤0.01% 1895

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schonfeld Strategic Advisors's ACRV Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Acrivon Therapeutics (ACRV) in Q1 2026, closing a stake of 16,428 shares — an estimated $39.6K sold.

Schonfeld Strategic Advisors first reported a position in ACRV in Q4 2025 and held it in 1 quarter. The position peaked at $39.6K in Q4 2025. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Acrivon Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 16,428 Acrivon Therapeutics shares in Q1 2026, an estimated $39.6K.
  • Schonfeld Strategic Advisors first reported a position in Acrivon Therapeutics in Q4 2025 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Acrivon Therapeutics position peaked at $39.6K in Q4 2025.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.